CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference

   CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare
                                  Conference

PR Newswire

ATLANTA, Nov. 6, 2012

ATLANTA, Nov. 6, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading
tissue processing and medical device company focused on cardiac and vascular
surgery, announced today that Steven G. Anderson, president and chief
executive officer of CryoLife, Inc., is scheduled to present in the upcoming
Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November
13, 2012 at 3:00 pm ET in New York City. 

CryoLife's live presentation may be accessed through its Web site,
www.cryolife.com, on the Investor Relations page.  An archived copy of the
presentation will be available for 90 days on the same Web site.

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution
of implantable living human tissues for use in cardiac and vascular surgeries
throughout the U.S., certain countries in Europe, and Canada.  CryoLife's
CryoValve^® SG pulmonary heart valve, processed using CryoLife's proprietary
SynerGraft^® technology, has FDA 510(k) clearance for the replacement of
diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary
valves.  CryoLife's CryoPatch^® SG pulmonary cardiac patch has FDA 510(k)
clearance for the repair or reconstruction of congenital heart defects.
 CryoLife's BioGlue^® Surgical Adhesive is FDA approved as an adjunct to
sutures and staples for use in adult patients in open surgical repair of large
vessels.  BioGlue is also CE marked in the European Community for use in soft
tissue repair and is approved in Japan for use in the repair of aortic
dissections.  Additional marketing approvals for BioGlue have been granted in
several other countries throughout the world.  CryoLife, through its
subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary
artery disease for severe angina using a laser console system and single use,
fiber-optic handpieces to perform a surgical procedure known as
Transmyocardial Revascularization (TMR).  In addition, CryoLife's subsidiary
Hemosphere, Inc. markets the HeRO^® Graft, which is a solution for end-stage
renal disease in certain hemodialysis patients.  CryoLife distributes
PerClot^®, an absorbable powder hemostat, in the European Community and other
select international countries.  CryoLife's BioFoam^™ Surgical Matrix is CE
marked in the European Community for use as an adjunct in the sealing of
abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by
ligature or other conventional methods is ineffective or impractical. 

For additional information about the company, visit CryoLife's website:
http://www.cryolife.com.

Contacts:

CryoLife                                          The Ruth Group
D. Ashley Lee                                     Nick Laudico / Zack Kubow
Executive Vice President, Chief Financial Officer 646-536-7030 / 7020
and Chief Operating Officer                       nlaudico@theruthgroup.com
Phone: 770-419-3355                               zkubow@theruthgroup.com

SOURCE CryoLife, Inc.

Website: http://www.cryolife.com